Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Gastroenterology

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2012.05.037PMID 22643350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901

  2012cited by this paper
• ORAL COMMUNICATIONSOC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE

  2012cited by this paper
• No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

  2011cited by this paper
• Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.

  2011cited by this paper
• Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

  2011cited by this paper
• Screening Colonoscopy in the Underserved Population: Report of the First Year of a No-Cost Colorectal Cancer Screening Program for the Underserved in Rhode Island

  2011cited by this paper
• Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

  2011cited by this paper
• Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

  2011cited by this paper
• 731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B

  2011cited by this paper
• Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

  2011cited by this paper
• Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

  2010cited by this paper
• Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

  2010cited by this paper
• Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

  2010cited by this paper
• Review: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B

  2010cited by this paper
• Chronic hepatitis B : an update

  2010cited by this paper
• Chronic hepatitis B: Update 2009

  2009cited by this paper
• Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

  2009cited by this paper
• Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

  2009cited by this paper
• Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

  2009cited by this paper
• EASL Clinical Practice Guidelines: management of chronic hepatitis B.

  2009cited by this paper
• Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

  2009cited by this paper
• Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

  2009cited by this paper
• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

  2008cited by this paper
• Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.

  2008cited by this paper
• Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

  2008cited by this paper
• Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

  2007cited by this paper
• Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management

  2007cited by this paper
• European Association for the Study of the Liver

  2006cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• 45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)

  2006cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.

  2005cited by this paper
• Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.

  2005cited by this paper
• Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B

  2002cited by this paper
• Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy

  2001cited by this paper

• mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress

  2025cites this paper
• Current Clinical Applications of Entecavir in Hepatitis B Viruses Infection

  2025cites this paper
• Opportunities and challenges for hepatitis B cure in people living with HIV and hepatitis B virus

  2025cites this paper
• Kinetics and predictors of Hepatitis B surface antigen (HBsAg) loss after commencing HBV-active antiretroviral therapy (ART) in the setting of HIV-and chronic HBV co-infection.

  2025cites this paper
• Management of Immune Tolerant Chronic Hepatitis B.

  2025cites this paper
• Indian National Association for the Study of the Liver Position Statements on Prevention, Diagnosis, and Management of Hepatitis B Virus Infection in India.

  2025cites this paper
• Entecavir for children and adults with chronic hepatitis B.

  2025cites this paper
• Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients

  2024cites this paper
• Real-world study on the efficacy and safety of different treatment regimens in treatment-naïve CHB patients with high viral load

  2024cites this paper
• Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments

  2024cites this paper
• Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment

  2024cites this paper
• Managing HBV and HCV Infection Pre- and Post-liver Transplant.

  2023cites this paper
• Entecavir for children and adults with chronic hepatitis B

  2023cites this paper
• CD4+ T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV/HBV coinfection during combined antiretroviral therapy

  2023cites this paper
• Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patients

  2022cites this paper
• Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B.

  2021cites this paper
• Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis

  2021cites this paper
• New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage

  2021cites this paper
• Nucleos(t)ide Therapy and Long-Term Outcomes

  2021cites this paper
• Tenofovir is Superior to Entecavir in Patients with Treatment-na € ıve Hepatitis B e-Antigen–Positive Chronic Hepatitis B

  2021cites this paper
• Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

  2021cites this paper
• Low-level viremia in nucleoside analog-treated chronic hepatitis B patients

  2021cites this paper
• Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B

  2021cites this paper
• Combination Therapy

  2021cites this paper
• Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B.

  2021cites this paper
• Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV

  2021cites this paper
• Entecavir is Safe and Effective in Long Term for the Treatment of Hepatitis B in Immunocompromised Children.

  2020cites this paper
• Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.

  2020cites this paper
• A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients.

  2020cites this paper
• The use of Ingaron® in the treatment of chronic viral hepatitis B

  2020cites this paper
• Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?

  2020cites this paper
• Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.

  2020cites this paper
• Dynamics of HBV Surface Antigen Related end Points in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis

  2020cites this paper
• Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development.

  2020cites this paper
• Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review

  2020cites this paper
• Challenges and opportunities for hepatitis B cure in the setting of HIV-hepatitis B virus co-infection.

  2020cites this paper
• No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic HBV Infection Treated With Entecavir vs Tenofovir.

  2020cites this paper
• Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

  2019cites this paper
• Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis

  2019cites this paper
• Taiwan consensus statement on the management of chronic hepatitis B.

  2019cites this paper
• Development and validation of a model for hepatitis B e antigen seroconversion in entecavir‐treated patients with chronic hepatitis B

  2019cites this paper
• PIN58 ARE PUBLISHED HEALTH ECONOMIC MODELS FOR CHRONIC HEPATITIS B APPROPRIATELY CAPTURING THE BENEFITS OF HBSAG LOSS?

  2019cites this paper
• Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea

  2019cites this paper
• Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review

  2019cites this paper
• Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy

  2018cites this paper
• Improvements in the management of chronic hepatitis B virus infection

  2018cites this paper
• Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score–Matched Study

  2018cites this paper
• A novel T-cell epitope in the transmembrane region of the hepatitis B virus envelope protein responds upon dendritic cell expansion

  2018cites this paper
• Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

  2018cites this paper
• Entecavir-based combination therapies for chronic hepatitis B

  2018influential citation
• Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance

  2018cites this paper
• Pain and Rash in a Stem Cell Transplant Recipient

  2018cites this paper
• Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

  2018cites this paper
• Perspectives and limitations for nucleo(t)side analogs in future HBV therapies.

  2018cites this paper
• Real-World Evidence for Nucleoside/Nucleotide Analogues in a 5-Year Multicentre Study of Antiviral-Naive Chronic Hepatitis B Patients in China: 52-Week Results

  2018cites this paper
• Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

  2018cites this paper
• Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg‐positive high viral load chronic hepatitis B

  2018cites this paper
• Chronic Hepatitis B Infection: A Review

  2018cites this paper
• Hepatitis B

  2018cites this paper
• Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks

  2018cites this paper
• Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir

  2017cites this paper
• UGT1A1∗28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients

  2017cites this paper
• Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy

  2017cites this paper
• Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection

  2017cites this paper
• Clinical Practice Guidelines EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver

  2017cites this paper
• Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa

  2017cites this paper
• Immune balance in Hepatitis B Infection: Present and Future Therapies

  2017cites this paper
• Week 4 viral load predicts long‐term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world

  2017cites this paper
• INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.

  2017cites this paper
• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2017cites this paper
• Detection of Hepatitis B Virus M204I Mutation by Quantum Dot-Labeled DNA Probe

  2017cites this paper
• Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

  2017cites this paper
• Treatment of hepatitis B virus with combination therapy now and in the future.

  2017cites this paper
• 155 – Drugs to Treat Viral Hepatitis

  2017cites this paper
• Hepatitis B and D

  2017cites this paper
• Hepatitis B Virus Drug Resistance

  2017cites this paper
• New Strategy Treating Hepatitis B Virus (HBV) Infection: A Review of HBV Infection Biology

  2017cites this paper
• Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China

  2017cites this paper
• Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver

  2017cites this paper
• Hepatitis B: 50 years after the discovery of Australia antigen.

  2016cites this paper
• Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B

  2016cites this paper
• AASLD guidelines for treatment of chronic hepatitis B

  2016cites this paper
• Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure

  2016cites this paper
• Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

  2016cites this paper
• Current treatments for chronic hepatitis B virus infections.

  2016cites this paper
• An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults

  2016influential citation
• A randomized clinical trial of peginterferon alpha‐2b with or without entecavir in patients with HBeAg‐negative chronic hepatitis B: Role of host and viral factors associated with treatment response

  2016cites this paper
• Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B

  2016cites this paper
• Innate responses CD 8 + cells B cells CD 4 + cells Adaptive immune responses Interferon alpha hNTCP Nucleos ( t ) ide analogues

  2016cites this paper
• Fourth Edition

  2016cites this paper
• Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients

  2016cites this paper
• A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.

  2016cites this paper
• Adefovir plus Entecavir Therapy in Chronic Hepatitis B Patients with Treatment Failure to Lamivudine-Entecavir Sequential Therapy: Outcome at 2 Years

  2015cites this paper
• Guidelines for Treatment of Chronic Hepatitis B

  2015cites this paper
• Current and future directions for treating hepatitis B virus infection.

  2015cites this paper
• Management of chronic hepatitis B infection

  2015cites this paper
• Randomized, three‐arm study to optimize lamivudine efficacy in hepatitis B e antigen‐positive chronic hepatitis B patients

  2015cites this paper
• [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]

  2015cites this paper
• Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.

  2015influential citation
• Low‐dose short‐term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post‐transplant hepatitis B virus prophylaxis?

  2015cites this paper